Drug intelligence / Profile preview

DWP707

Development stage: Preclinical
Lead developer: Daewoong Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

DWP707 is a recombinant protein therapeutic being developed by Daewoong Pharmaceutical and its US-based subsidiary, Great Bear Pharmaceutical, for the treatment of dry eye syndrome. The drug is currently in the early stages of development, with a specific focus on the United States market. As a recombinant protein, DWP707 is designed to address the symptoms or underlying causes of dry eye, though its specific biological target has not been publicly disclosed in the company's pipeline documentation.

Beyond the preview

Go deeper on DWP707.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP707.

Explore the full profile